Leqvio FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 18, 2025.
FDA Approved: Yes (First approved December 22, 2021)
Brand name: Leqvio
Generic name: inclisiran
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: High Cholesterol, Familial Heterozygous
Leqvio (inclisiran) is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA used to reduce low-density lipoprotein cholesterol (LDL-C).
- Leqvio is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
- Leqvio is administered via subcutaneous injection every six months, after the initial dose and another dose at three months.
- Common adverse reactions (≥ 3%) include injection site reaction, arthralgia, and bronchitis.
Development timeline for Leqvio
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.